Oncolytic adenoviruses armed with heterologous genes

Inventors

CHAMPION, BRIAN ROBERT • BROWN, Alice Claire Noel • Fisher, Kerry David • NICOLSON, Tamara

Assignees

Akamis Bio Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11938159-B2

Patent

Publication Date

2024-03-26

Expiration Date


Abstract

The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR wherein: B1 is bond or comprises: E1A, E1B or E1A-E1B; BA comprises-E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.

Core Innovation

The invention relates to Enadenotucirev (EnAd) viruses and plasmids, including oncolytic group B adenoviruses engineered to include heterologous transgenes inserted in genome regions adjacent to the L5 gene. The engineering places defined DNA segments in a region at the 3′ end of the L5 gene, with unique restriction sites inserted in L5-adjacent insertion regions and sequence boundaries defined by SEQ ID NOs and specified nucleotide locations.

The genome engineering uses defined EnAd genome/transgene constructs, including regions Bx and By and sequence definitions for EnAd genome constructs with inserts in regions Bx and By, including NG-185/NG-139. The document further describes transgene cassettes and controlled or replaceable transgene insertion via unique restriction sites within the L5-adjacent insertion region, with promoter options including endogenous promoters such as the E4 promoter and major late promoter and exogenous promoters such as CMV.

The described constructs include therapeutic payloads such as antibody constructs, cytokines, tumour antigen NY-ESO-1, sodium iodide symporter, and shRNA, including GAPDH shRNA, together with splice acceptor elements, promoters, IRES, poly(A), and peptide tags. The partial content states that inserting unique restriction sites does not significantly alter oncolytic activity or viral replication compared to control EnAd, while still enabling transgene expression.

Claims Coverage

The claim coverage centers on one independent claim directed to a plasmid, with multiple dependent claims refining the Enadenotucirev genome definition, the placement and content of unique restriction sites, and the transgene content; at least one dependent claim also extends to a production method using host-cell introduction.

Enadenotucirev plasmid with 3′-end-of-L5 unique restriction-site insert

A plasmid comprising a p15A bacterial origin of replication and a kanamycin resistance gene, including an Enadenotucirev genome sequence comprising an L5 gene and a DNA sequence comprising one or more unique restriction sites inserted in a region located at the 3′ end of the L5 gene, wherein the region comprises SEQ ID NO: 11 and the DNA sequence is comprised between nucleotides 12 and 13 in SEQ ID NO: 11 or between a place corresponding to nucleotides 29356 and 29357 in SEQ ID NO: 12.

Direct junction of insert at an end of L5 coding or non-coding sequence

The plasmid further includes a region directly joined to a base of L5 that marks the end of a coding sequence of L5 or the end of a non-coding sequence of L5.

One or two restriction sites with at least one transgene

The DNA sequence contains one or two restriction sites and at least one transgene.

One or two restriction sites with exactly two transgenes

The DNA sequence includes one or two restriction sites and two transgenes.

Enadenotucirev genome sequence corresponding to SEQ ID NO: 12

The plasmid includes an Enadenotucirev genome sequence corresponding to SEQ ID NO: 12.

Production of an Enadenotucirev adenovirus using a host cell with a post-L5 cassette

A method for producing an adenovirus by introducing a plasmid into a host cell, wherein the plasmid carries a transgene cassette inserted after the L5 gene, resulting in the adenovirus Enadenotucirev.

Overall, the claim coverage centers on an Enadenotucirev-containing plasmid engineered to place a DNA sequence with one or more unique restriction sites in a region at the 3′ end of the L5 gene, with SEQ ID NO.-defined placement constraints and further limitations on restriction-site count and transgene content; at least one dependent claim also covers producing an Enadenotucirev adenovirus by host-cell introduction of a plasmid carrying a transgene cassette inserted after L5.

Stated Advantages

Inserting unique restriction sites does not significantly alter oncolytic activity or viral replication compared to control EnAd.

The unique restriction-site design enables transgene expression while maintaining replication/oncolysis.

Tolerating the insertion near L5 without compromising replication behavior described in the document.

Documented Applications

EnAd-derived viruses expressing inserted transgenes are produced from plasmids and compared by assays, including cell viability/oncolytic activity and virus replication measurements.

The partial content documents application to in vivo tumour models (xenograft mouse models) to support maintained replication/oncolysis alongside transgene expression.

Cancer treatment using engineered oncolytic group B adenoviruses such as Enadenotucirev armed with therapeutic antibody or antibody-binding fragment payloads and other payloads.

Expression of therapeutic antibodies or antibody-binding fragments including anti-VEGF, full-length and scFv, anti-PD-L1, and anti-CTLA-4 using endogenous or exogenous promoters as described in the document.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.